Business Wire

MN-DIGI-INTERNATIONAL

7.11.2022 14:01:45 CET | Business Wire | Press release

Share
Digi International Unveils Digi XBee RR Module and Rapid Redesign Services, Slashing Time-to-Market for Designers, OEMs, and Solution Providers

Digi International® (NASDAQ: DGII), a leading global provider of Internet of Things (IoT) connectivity solutions, today unveiled the Digi XBee® RR, a wireless networking module to support IoT solutions within the XBee ecosystem. Digi XBee RR offers immediate availability and dramatically reduces time-to-market for designers, OEMs, and solution providers by providing off-the-shelf, pre-certified wireless connectivity and easy-to-add functionality. For customers needing immediate assistance in transitioning to this available module, Digi is also offering its Digi XBee Rapid Redesign Services.

Building on industry-leading technology, the low-power, low-profile Digi XBee RR module gives designers the ability to switch among multiple frequencies and wireless protocols with a fully interoperable Digi XBee ecosystem to support a range of applications spanning building automation, smart energy, digital health, intelligent lighting, and more.

Immediately Available Module Opens Up Product Development Options
Digi XBee RR modules are in stock and available to order today for immediate delivery from Digi's global distributor network. The XBee RR line includes modules with different form factors, wireless protocols and antenna options to provide an easy transition from existing XBee 3 designs.

“The release of our XBee RR gives engineers and developers an immediately available, pre-certified wireless module in what has been a very difficult, component-constrained environment,” said Steve Ericson, Vice President and General Manager of Digi’s OEM Solutions division. “In addition to the available-now Digi XBee RR, Digi has its IX15 gateway and Digi Remote Manager®, providing developers a complete device-to-cloud IoT solution.”

From edge computing to future migration, the size, weight, power, and performance advantages of Digi XBee RR are ideal for scalable device connectivity. With Digi Remote Manager, it’s easy for network managers to configure, monitor, and control Digi XBee RR modules via a gateway from a simple, central platform. Built-in Digi TrustFence® security, identity, and data privacy features tap into more than 175 controls to protect against new and evolving cyber threats. Digi XBee Mobile App and Digi XCTU® software tools simplify setup, configuration, testing, and adding/changing functionality.

Expert Help Available to Speed Time-to-Market
To fully support customers with Digi XBee RR design, Digi Wireless Design Services is offering a Digi XBee Rapid Redesign Service. These services include design consultation, customized transition plan for replacing an existing embedded module, and testing for unintended EMI produced.

The Digi XBee ecosystem’s software, gateways, and cloud connectivity deliver unparalleled support for short-range networking systems with ZigBee®, 802.15.4 and Digi’s patented DigiMesh® protocols, as well as Bluetooth provisioning.

Digi XBee RR is available now. For more information, visit: https://www.digi.com/xbee-rr

About Digi International
Digi International (NASDAQ: DGII) is a leading global provider of IoT connectivity products, services, and solutions. It helps companies create next-generation connected products and deploy and manage critical communications infrastructures in demanding environments with high levels of security and reliability. Founded in 1985, Digi has helped customers connect more than 100 million things and counting. For more information, visit www.digi.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221107005014/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202629.8.2026 23:54:00 CEST | Press release

Qarmousha Pure Ultra White falcon sells for AED 1.5 million at the Abu Dhabi International Hunting and Equestrian Exhibition 2026 (ADIHEX) falcon auction Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon

Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release

MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot

Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release

Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me

BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release

Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro

Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release

Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye